Page 110 - Haematologica Vol. 110 - January 2025

ARTICLE - Pirtobrutinib in patients with prior intolerance to BTKi N.N. Shah et al.
lymphocytic leukemia: a UK and Ireland analysis of outcomes in
315 patients. Haematologica. 2016;101(12):1563-1572.
6. Estupiñán HY, Berglöf A, Zain R, Smith CIE. Comparative analysis
of BTK inhibitors and mechanisms underlying adverse effects.
Front Cell Dev Biol. 2021;9:630942.
7. Rogers KA, Thompson PA, Allan JN, et al. Phase II study of
acalabrutinib in ibrutinib-intolerant patients with relapsed/ refractory chronic lymphocytic leukemia. Haematologica. 2021;106(9):2364-2373.
8. Shadman M, Flinn IW, Levy MY, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol. 2023;10(1):e35-e45.
9. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892-901.
10. Gomez EB, Ebata K, Randeria HS, et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023;142(1):62-72.
11. Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389(1):33-44.
12. Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41(24):3988-3997.
13. Telaraja D, Kasamon YL, Collazo JS, et al. FDA approval summary: pirtobrutinib for relapsed or refractory mantle cell lymphoma. Clin Cancer Res. 2024;30(1):17-22.
14. US Food and Drug Administration. FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma. 2023. https://www.fda.gov/drugs/ resources-information-approved-drugs/fda-grants-accelerated- approval-pirtobrutinib-chronic-lymphocytic-leukemia-and- small-lymphocytic#:~:text=On%20December%201%2C%20 2023%2C%20the%20Food%20and%20Drug,including%20a%20 BTK%20inhibitor%20and%20a%20BCL-2%20inhibitor Accessed December 15, 2023.
15. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456. Erratum in Blood. 2008;112(13):5259].
16. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
17. Jensen JL, Mato AR, Pena C, Roeker LE, Coombs CC. The potential of pirtobrutinib in multiple B-cell malignancies. Ther Adv Hematol. 2022;13:20406207221101697.
18. Cameron F, Sanford M. Ibrutinib: first global approval. Drugs. 2014;74(2):263-271.
19. Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138-140.
20. Brown JR, Moslehi J, Ewer MS, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol. 2019;184(4):558-569.
21. Chen ST, Azali L, Rosen L, et al. Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. J Hematol Oncol. 2022;15(1):92.
22. Hampel PJ, Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022;12(11):161.
23. Kay NE, Hampel PJ, Van Dyke DL, Parikh SA. CLL update 2022: a continuing evolution in care. Blood Rev. 2022;54:100930.
24. Pérez-Carretero C, González-Gascón-Y-Marín I, Rodríguez- Vicente AE, et al. The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment. Diagnostics (Basel). 2021;11(5):853.
25. Sharman JP, Biondo JML, Boyer M, et al. A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies. EJHaem. 2022;3(2):492-506.
Haematologica | 110 January 2025
102